معرفی
Maya Thanou is a Professor of Pharmaceutical Nanotechnology at King’s College London, based in the Institute of Pharmaceutical Science within the School of Cancer & Pharmaceutical Sciences. She holds a PhD from LACDR (Leiden/Amsterdam Centre for Drug Research) and has held academic roles at Cardiff University (Lecturer) and Imperial College London (via a Dorothy Hodgkin Royal Society Fellowship). Her research focuses on engineering image-guided drug delivery systems using nanoparticles and nanomaterials, with emphasis on theranostic applications, focused ultrasound, and MRI-guided therapies. Key areas include nanomaterials for microwave imaging, biocompatible quantum dots, and siRNA delivery. She collaborates with industry and holds 10 patents, co-editing an RSC book on theranostics. Awards include the AAPS Graduate Research Award (2000) and the Royal Society Fellowship (2004).
- Education: PhD in Pharmaceutical Sciences (LACDR, 2000)
- Key Roles: Director of MSc Pharmaceutical Technology Programme, Principal Investigator on multiple grants (EPSRC, BBSRC, CRUK, etc.)
- Research Themes:
- Theranostic nanoparticles for tumour treatment
- MRI/focused ultrasound drug delivery
- Nano-bio interface engineering
- Contrast agents for microwave imaging
Her work spans 80+ publications and multiple collaborative projects, including recent initiatives on brain tumour drug delivery (Brain Tumour Charity-funded) and STING agonist immunotherapy for paediatric gliomas (CRUK-funded). She also co-founded Apeikon Therapeutics, a spinout from King’s focusing on nanomedicine innovations.
